Imunon (IMNN) Chairman Michael Tardugno Buys $73K of Stock
Executive Chairman Michael Tardugno bought 42,519 shares of IMNN at $1.72 per share.
Reviewed by automated data checks against the source filing. How we make and check alerts
Michael Tardugno, Executive Chairman of Board at Imunon, Inc. ($IMNN), bought 42,519 shares at an average price of $1.72, worth about $73,132.68, on June 25, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $IMNN is up 11.1% after 1 week, down 11.1% after 1 month and down 40.7% to date (from the $1.72 close on Jun 25, 2026).
IMNN
Imunon, Inc.
Key Points
- On June 25, 2026, Executive Chairman Michael Tardugno bought 42,519 shares of IMNN at $1.72 each.
- Shares of IMNN traded near $1.80 on Tuesday amid insider buying activity.
- Maxim Group initiated coverage on IMNN with a buy rating and a $10 price target in April 2026.
Get $IMNN trade alerts by text
We text you when insiders, Congress or big funds trade $IMNN. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Imunon, Inc. alert may contain errors. Disclosures
Michael Tardugno, the Executive Chairman of IMNN, recently increased his stake in the company. On June 25, 2026, Tardugno purchased 42,519 shares at an average price of $1.72 per share, totaling $73,132.68. This move underscores his confidence in the company's prospects.
Insider Buying and Selling at Imunon, Inc.
The recent insider activity at IMNN included several key figures from the company. Alongside Michael Tardugno, who bought a total of 42,519 shares, Chief Medical Officer Douglas Vincent Faller acquired 21,896 shares at the same price of $1.72 on June 25. Stacy Lindborg, the President and CEO, purchased 67,150 shares on the same day, also at $1.72 per share. Earlier in June, Lindborg and Tardugno made additional purchases at slightly higher prices.
Other Institutional Activity in IMNN
Institutional investors have also been active in IMNN. Armistice Capital, LLC grew its holdings by 81,444 shares, ending with 348,330 shares valued at approximately $1.02 million, representing a 30.5% increase. Vanguard Capital Management LLC opened a new position with 48,056 shares worth about $141,285. Geode Capital Management, LLC increased its stake by 11,989 shares, bringing its total to 33,211 shares valued at $97,644, marking a 56.5% increase. Meanwhile, Riverview Capital Advisers, LLC maintained its position with 34,364 shares.
Analysts Set New Price Targets
Analysts have been optimistic about IMNN's potential. On April 17, 2026, Maxim Group initiated coverage on the stock with a buy rating and a price target of $10. This reflects strong expectations for the company's future performance.
About IMNN
IMNN operates in the biotechnology sector, focusing on developing innovative therapies for unmet medical needs. The company is dedicated to advancing its pipeline of products to improve patient outcomes. With headquarters in the United States, IMNN is led by a team of experienced executives committed to driving growth and scientific progress.
Bottom Line
Michael Tardugno's recent purchase of IMNN shares highlights insider confidence in the company's future. This activity, along with institutional moves and positive analyst coverage, suggests that the market is keeping a close eye on IMNN's developments. As always, it's important to remember that insider transactions can be part of a broader strategy and may not necessarily indicate the company's current financial health or future stock performance.
Related Filing Alerts
Source: Michael Tardugno's Form 4 filing on $IMNN (Jun 25, 2026). Find the original filing: IMNN Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts